ClinicalTrials.gg
CompletedNCT04255277Updated Sep 22, 2025

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

A Phase 1 interventional study of Combined oral contraceptives (COC) and Moxifloxacin 400mg in Healthy Subjects, sponsored by Viatris Innovation GmbH. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants.

Participants will be randomly assigned to one of the 4 treatments: placebo, cenerimod 0.5 mg, cenerimod 4 mg or moxifloxacin.

Read the detailed description

Participants randomized in one of the cenerimod or placebo groups will receive combined oral contraceptives on Day 1 (i.e., prior to cenerimod or placebo administration, Period 1) and on Day 42 (i.e., 36 days after the stat of cenerimod or placebo, Period 2).

Half of the participants randomized in one of the cenerimod or placebo groups will be enrolled in an accelerated elimination procedure part (Period 3).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • of 18.0 to 29.9 kg/m\^2 (inclusive) at the screening.
  • No findings on the physical examination at screening.
  • Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 45 to 90 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on Day -1.
  • 12-lead without clinically relevant abnormalities, measured after 5 min in the supine position at screening and on admission.
  • No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) at screening and on admission.
  • Negative results from urine drug screen and breath alcohol tests at screening and on admission.
  • Women of non- (i.e., [defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicle-stimulating hormone test], with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure [confirmed by a specialist]).
  • Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (from screening, during the entire study, and up to end-of-study) a highly effective method of with a failure rate of less than 1% per year (i.e., intrauterine device, bilateral tubal occlusion) or be sexually inactive, or have a vasectomized partner. Hormonal contraceptive must not be used within 3 months prior to screening until end of study visit.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to cenerimod.
  • Previous exposure to combined oral (s), moxifloxacin, or charcoal within 3 months prior to screening.
  • Known to treatments of the same class as cenerimod, or any of the .
  • Known hypersensitivity to combined oral contraceptive(s), moxifloxacin, or charcoal or treatments of the same class, or any of their excipients.
  • Any to combined oral contraceptive(s) or moxifloxacin treatment.
  • Known hypersensitivity or allergy to natural rubber latex.
  • Lymphopenia (\< 1000 cells/μL) at Screening and on Day -1.
  • Familial history of sick-sinus syndrome.
  • Any cardiac condition or illness (including abnormalities) with a potential to increase the cardiac risk of the subject based on the standard 12-lead ECG at screening.
  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation.
  • history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Any treatment within 6 weeks or 5 terminal half-lives (t½), whichever is longer, before first study drug administration.
  • History or clinical evidence of alcoholism or drug abuse.
  • Excessive caffeine consumption, defined as 800 mg or more per day at screening.
  • Nicotine consumption within 3 months prior to screening and inability to refrain from nicotine consumption.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals).
  • Viral, fungal, bacterial or protozoal infection and / or serology.
  • History of deep vein thrombophlebitis or thromboembolic disorders.
  • Legal incapacity or limited legal capacity at screening.
  • Pregnant or lactating women.
  • History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Other
    Period 1: First administration of combined oral contraceptives

    Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.

    Drug: Combined oral contraceptives (COC)

  • Other
    Period 2: Second administration of Combined Oral Contraceptive

    Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.

    Drug: Combined oral contraceptives (COC) · Drug: Cenerimod 0.5 mg · Drug: Cenerimod 4 mg

  • Experimental
    Period 2: Cenerimod 0.5 mg

    Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.

    Drug: Combined oral contraceptives (COC)

  • Experimental
    Period 2: Cenerimod 4 mg

    Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.

    Drug: Combined oral contraceptives (COC)

  • Other
    Period 2: Moxifloxacin

    Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.

    Drug: Moxifloxacin 400mg

  • Placebo comparator
    Period 2: Placebo

    Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.

    Drug: Matching Placebo

  • Experimental
    Period 3: Cenerimod 0.5 mg and charcoal

    Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.

    Drug: Cenerimod 0.5 mg · Other: Charcoal, activated

  • Experimental
    Period 3: Cenerimod 4 mg and charcoal

    Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.

    Drug: Cenerimod 4 mg · Other: Charcoal, activated

  • No intervention
    Period 3: Cenerimod elimination period

    Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.

Interventions

  • DrugCombined oral contraceptives (COC)

    Drug page: Contraceptives, Oral, Combined

    A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

    Also known as: Levonorgestrel/Ethinylestradiol

  • A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.

  • This will be administered orally as a film-coated tablet in the morning.

    Also known as: ACT-334441

  • This will be administered orally as a film-coated tablet in the morning.

    Also known as: ACT-334441

  • OtherCharcoal, activated

    Granules for oral suspension will be used and administered open-label.

    Also known as: Carbomix 50g

  • DrugMatching Placebo

    Cenerimod matching placebo tablets will be administered once daily orally in the morning.

06

What researchers measure

Primary outcomes

  1. Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)

    ECG variables will be assessed from ECGs extracted in replicates at predefined time points from continuous 24 hour Holter ECG recordings.

    Time frame: Day 6, 7, 14, 21, 35, and 56.

  2. Maximum plasma concentration (Cmax): levonorgestrel

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  3. Maximum plasma concentration (Cmax): ethinylestradiol

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  4. Time to reach Cmax (tmax): levonorgestrel

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  5. Time to reach Cmax (tmax): ethinylestradiol

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  6. The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): levonorgestrel

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  7. The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): levonorgestrel

    Blood samples for determination of PK parameters will be collected at predefined

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  8. The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): ethinylestradiol

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  9. The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): ethinylestradiol

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 1 to Day 3; Day 42 to Day 44

  10. Terminal elimination half-life (t1/2): levonorgestrel

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 56 to Day 68

  11. Terminal elimination half-life (t1/2): ethinylestradiol

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 56 to Day 68

  12. Terminal elimination half-life (t1/2): cenerimod

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 56 to Day 68

  13. Area under the plasma concentration-time curve (AUC) from Day 56 to infinity (AUC56-inf) for cenerimod

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 56 to Day 68

Secondary outcomes

  1. Change from baseline in total lymphocyte count to each time point

    Blood samples (fasting) collected at predefined time points as part of the normal hematology analysis.

    Time frame: Day 5, Day 7, Day 14, Day 21, Day 35, Day 56, Day 57, Day 58, Day 1, Day 64, and Day 67

  2. Maximum plasma concentration (Cmax): cenerimod

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 7, Day 14, Day 21, Day 35, and Day 56

  3. Time to reach Cmax (tmax): cenerimod

    Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.

    Time frame: Day 7, Day 14, Day 21, Day 35, and Day 56

07

Study locations

1 site
  • Site 1
    Rennes, 35042, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2021, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Feb 5, 2020
StartActual
Jan 31, 2020
Primary completionActual
Sep 14, 2021
CompletionActual
Oct 18, 2021
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04255277
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jan 31, 2020
Primary completion
Sep 14, 2021
Completion
Oct 18, 2021
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Contraceptives, Oral, Combined · Moxifloxacin · Cenerimod

Start the discussion